Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALECNASDAQ:BRNSNASDAQ:LYELNASDAQ:TLSA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALECAlector$1.54-4.9%$1.20$0.87▼$6.78$153.99M0.71796,731 shs408,838 shsBRNSBarinthus Biotherapeutics$0.93+1.9%$0.87$0.64▼$1.94$37.60M-0.7836,731 shs6,567 shsLYELLyell Immunopharma$9.74$8.97$7.65▼$53.30$144.23M-0.2667,897 shs76,722 shsTLSATiziana Life Sciences$1.55+9.2%$1.29$0.63▼$1.91$181.11M-0.09471,998 shs1.05 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALECAlector-0.61%+14.89%+45.95%+11.72%-65.53%BRNSBarinthus Biotherapeutics-7.08%-7.65%+0.49%-13.75%-51.88%LYELLyell Immunopharma+3.51%-15.01%+20.37%-16.81%-80.98%TLSATiziana Life Sciences-2.74%+0.71%-12.35%-9.55%+74.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALECAlector3.5252 of 5 stars3.11.00.04.52.81.70.0BRNSBarinthus Biotherapeutics2.86 of 5 stars3.53.00.00.02.70.81.3LYELLyell Immunopharma3.1556 of 5 stars2.83.00.00.03.15.00.6TLSATiziana Life Sciences1.2262 of 5 stars0.05.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALECAlector 2.14Hold$4.00159.74% UpsideBRNSBarinthus Biotherapeutics 3.00Buy$6.25570.60% UpsideLYELLyell Immunopharma 1.50Reduce$20.00105.34% UpsideTLSATiziana Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BRNS, LYEL, TLSA, and ALEC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $10.004/16/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.003/24/2025BRNSBarinthus BiotherapeuticsAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/21/2025BRNSBarinthus BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$3.00 ➝ $3.003/13/2025LYELLyell ImmunopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$20.00 ➝ $20.00(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALECAlector$88.34M1.74N/AN/A$1.41 per share1.09BRNSBarinthus Biotherapeutics$14.97M2.51N/AN/A$4.85 per share0.19LYELLyell Immunopharma$65K2,218.92N/AN/A$2.60 per share3.75TLSATiziana Life SciencesN/AN/AN/AN/A$0.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALECAlector-$130.39M-$1.26N/AN/AN/A-257.54%-108.77%-27.03%8/6/2025 (Estimated)BRNSBarinthus Biotherapeutics-$73.35M-$1.64N/AN/AN/AN/A-34.26%-29.30%8/6/2025 (Estimated)LYELLyell Immunopharma-$234.63M-$25.00N/AN/AN/A-323,792.09%-34.64%-30.02%8/6/2025 (Estimated)TLSATiziana Life Sciences-$17.69MN/A0.00∞N/AN/AN/AN/AN/ALatest BRNS, LYEL, TLSA, and ALEC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LYELLyell Immunopharma-$3.80-$3.60+$0.20-$0.18N/A$0.01 million5/7/2025Q1 2025BRNSBarinthus Biotherapeutics-$0.34-$0.49-$0.15-$0.49N/AN/A3/20/2025Q4 2024BRNSBarinthus Biotherapeutics-$0.50-$0.51-$0.01-$0.51N/A$14.97 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALECAlectorN/AN/AN/AN/AN/ABRNSBarinthus BiotherapeuticsN/AN/AN/AN/AN/ALYELLyell ImmunopharmaN/AN/AN/AN/AN/ATLSATiziana Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALECAlectorN/A3.293.29BRNSBarinthus BiotherapeuticsN/A8.938.93LYELLyell ImmunopharmaN/A13.4313.43TLSATiziana Life SciencesN/A0.85N/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALECAlector85.83%BRNSBarinthus Biotherapeutics25.20%LYELLyell Immunopharma66.05%TLSATiziana Life SciencesN/AInsider OwnershipCompanyInsider OwnershipALECAlector9.10%BRNSBarinthus Biotherapeutics10.70%LYELLyell Immunopharma25.10%TLSATiziana Life Sciences39.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALECAlector27099.99 million89.02 millionOptionableBRNSBarinthus Biotherapeutics10740.34 million37.01 millionN/ALYELLyell Immunopharma27014.81 million218.83 millionOptionableTLSATiziana Life Sciences8116.85 million63.43 millionOptionableBRNS, LYEL, TLSA, and ALEC HeadlinesRecent News About These CompaniesTiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosingJune 13 at 11:03 AM | proactiveinvestors.comTiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis CenterJune 13 at 10:30 AM | globenewswire.comTiziana Life Sciences to Present at the Bio International ConventionJune 13 at 8:30 AM | globenewswire.comTiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Still a Buy?May 28, 2025 | marketbeat.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s DiseaseMay 23, 2025 | finance.yahoo.comTiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's DiseaseMay 23, 2025 | globenewswire.comJournal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's DiseaseMay 15, 2025 | finance.yahoo.comTiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study showsMay 15, 2025 | proactiveinvestors.comTiziana Life Sciences reports purchase of shares by chairmanMay 12, 2025 | msn.comTiziana Life Sciences Announces Purchase of Shares by ChairmanMay 12, 2025 | globenewswire.comTiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumabMay 9, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal ForalumabMay 9, 2025 | globenewswire.comTiziana Life Sciences’ intranasal MS candidate shows promise in open-label studyMay 8, 2025 | pmlive.comTiziana shares surge 21% on promising multiple sclerosis dataMay 6, 2025 | proactiveinvestors.comTiziana reports encouraging results for nasal MS drug in early studyMay 6, 2025 | proactiveinvestors.comTiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple SclerosisMay 6, 2025 | globenewswire.comWhy Tiziana Life Sciences Ltd (TLSA) is Surging in 2025April 30, 2025 | insidermonkey.comTiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of MassachusettsApril 23, 2025 | proactiveinvestors.comTiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis TrialApril 23, 2025 | globenewswire.comTiziana Life announces dosing at JHU, part of Phase 2 trial of foralumabApril 3, 2025 | markets.businessinsider.comTiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns HopkinsApril 2, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBRNS, LYEL, TLSA, and ALEC Company DescriptionsAlector NASDAQ:ALEC$1.54 -0.08 (-4.94%) Closing price 04:00 PM EasternExtended Trading$1.54 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Barinthus Biotherapeutics NASDAQ:BRNS$0.93 +0.02 (+1.94%) Closing price 03:57 PM EasternExtended Trading$0.88 -0.05 (-5.04%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.Lyell Immunopharma NASDAQ:LYEL$9.74 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$9.78 +0.04 (+0.46%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Tiziana Life Sciences NASDAQ:TLSA$1.55 +0.13 (+9.15%) Closing price 04:00 PM EasternExtended Trading$1.55 0.00 (0.00%) As of 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
